B
BG Medicine
Life sciences company developing biomarker-based diagnostic tests for the cardiovascular sectors
About BG Medicine
BG Medicine Inc. specializes in developing and commercializing diagnostic tests that provide critical insights into chronic heart failure. Operating in the healthcare diagnostics market, BG Medicine serves healthcare providers and clinical laboratories. The company's core product, the BGM Test, is an in vitro diagnostic device that measures galectin-3 levels in serum or plasma. This test aids in assessing the prognosis of patients diagnosed with chronic heart failure by providing quantitative data on galectin-3, a biomarker associated with cardiac fibrosis and remodeling. BG Medicine generates revenue through the sale of its diagnostic kits and related services. The business model focuses on leveraging its proprietary technology to offer reliable and precise diagnostic tools that enhance clinical decision-making and patient outcomes.
Source: Dealroom company dataAt a glance
- Founded
- 2000
- Headquarters
- Waltham, United States
- Listing
- IPO 2011
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning BG Medicine.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later4 investors entered at this stage
GE Asset Management- SFSmallcap World Fund
Gilde Healthcare
GE Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BG Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BG Medicine on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.